Interactions : אינטראקציות

8 DRUG INTERACTIONS
8.1 Drugs Having Clinically Important Interactions with ARIPLY Table 19: Clinically Important Drug Interactions with ARIPLY:

Concomitant          Clinical Rationale         Clinical Recommendation Drug Name or
Drug Class
Strong CYP3A4        The concomitant use of
Inhibitors (e.g.,    ABILIFY with strong        With concomitant use of itraconazole,        CYP 3A4 or CYP2D6          ABILIFY with a strong clarithromycin) or   inhibitors increased the   CYP3A4 inhibitor or strong CYP2D6        exposure of aripiprazole   CYP2D6 inhibitor, reduce inhibitors (e.g.,    compared to the use of     the ABILIFY quinidine,           ABILIFY                    dosage [see Dosage and fluoxetine,          alone [see Clinical        Administration (3.7)].
paroxetine)          Pharmacology (13.3)].
The concomitant use of
ARIPLY and
With concomitant use of carbamazepine
Strong CYP3A4                                   ARIPLY with a strong decreased the exposure
Inducers (e.g.,                                 CYP3A4 inducer, consider of aripiprazole carbamazepine,                                  increasing the ARIPLY compared to the use of rifampin)                                       dosage [see Dosage and ARIPLY
Administration (3.7)].
alone [see Clinical
Pharmacology (13.3)].
Due to its alpha
Antihypertensive                        Monitor blood pressure and adrenergic antagonism,
Drugs                                   adjust dose aripiprazole has the


36
Table 19: Clinically Important Drug Interactions with ARIPLY: 
Concomitant        Clinical Rationale          Clinical Recommendation Drug Name or
Drug Class potential to enhance the accordingly [see Warnings effect of certain        and Precautions (6.8)].
antihypertensive agents.
The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The Monitor sedation and blood
Benzodiazepines orthostatic hypotension pressure. Adjust dose
(e.g., lorazepam) observed was greater      accordingly.
with the combination as compared to that observed with lorazepam alone [see Warnings and Precautions (6.8)].



8.2 Drugs Having No Clinically Important Interactions with ARIPLY Based on pharmacokinetic studies, no dosage adjustment of ARIPLY is required when administered concomitantly with famotidine, valproate, lithium, lorazepam.
In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin, escitalopram), or CYP3A4 (e.g., dextromethorphan) when co-administered with aripiprazole. Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with aripiprazole [see Clinical Pharmacology (13.3)].